Sign In
Buy TRCK
$0.643
-0.0072 (-1.11%)
At Close: Jul 31, 2026
Sjögren's disease (SjD) is a prevalent, debilitating autoantibody disease with no FDA-approved advanced treatments The Company is actively enrolling patients in the Phase 3 DAFFODIL study T
Cheniere Energy Growth on Track, But Is It Worth Buying Now?
09:15am, Monday, 17'th Mar 2025
Companies like Cheniere Energy have invested billions into infrastructure that chills, liquefies, and loads natural gas onto specialized tankers for export.
Amazon Stock Regains Some Ground But Still On Track For Sixth Straight Weekly Decline
11:42am, Friday, 14'th Mar 2025
Amazon hasn't fallen for this many consecutive weeks since mid-2022. The post Amazon Stock Regains Some Ground But Still On Track For Sixth Straight Weekly Decline appeared first on Investor's Busines
Vail's $100 Million Cost Efficiency Plan Remains on Track
03:30am, Thursday, 13'th Mar 2025
Vail Resorts' (MTN -2.23%) fiscal second quarter 2025 earnings call, held on March 10, 2025, revealed important insights for investors following the winter ski season. CEO Kirsten Lynch and CFO Angela
Inditex Expansion Plan on Track Amid Fierce Competition in Fast Fashion
03:06am, Wednesday, 12'th Mar 2025
The owner of fashion brand Zara said store and online sales rose 4% at constant currency compared with the prior-year period.
OKYO Pharma seeks FDA Fast Track designation for neuropathic corneal pain treatment
09:09am, Monday, 10'th Mar 2025
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has filed a Fast Track designation application with the US Food and Drug Administration (FDA) for urcosimod, for the treatment of neuropathic corneal pa
Davide Campari: Simon Hunt Seems On Track To Revolutionize This Company
09:28am, Wednesday, 05'th Mar 2025
Campari's FY2024 report shows positive market reaction, driven by strong brand performance and strategic focus on efficiency and cost control under new CEO Simon Hunt. Despite challenges, Campari's Ap
Stella-Jones: On Track For A Solid 2025 (Rating Upgrade)
08:44am, Wednesday, 05'th Mar 2025
Stella-Jones, a hidden gem in the Material sector, offers better margins and growth with its railway ties and utility poles business. Strong Q4'24 results with revenue up 6% YoY and EPS beating estima
Lionsgate Studios, Starz Split On Track For Mid To Late April Close, CFO Says – Update
04:54pm, Tuesday, 04'th Mar 2025
Lionsgate CFO James Barge said today the company is on track to close the separation of Lionsgate Studios and Starz by mid-to-late April. During a Q&A at the Morgan Stanley media conference he said th
Rocket Lab Earnings: Neutron On Track But Volatility Reigns
02:48am, Friday, 28'th Feb 2025
Rocket Lab is selling off after hours to continue a recent downtrend. Neutron remains on track, but a guidance miss and broader market sell-off make the short-term risky. The current price could offer
ConnectM Retires Additional $1.9 Million Debt, Eliminating $31M in Total Liabilities to Date - On Track to be Debt-free by Q2 2025
08:00am, Thursday, 27'th Feb 2025
~ Currently operating at a $45M revenue run rate ~ ~ On Track to Achieve Operating Cash Flow Breakeven in Q1 2025 ~ MARLBOROUGH, Mass. , Feb. 27, 2025 /PRNewswire/ -- ConnectM Technology Solutions, In
Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs
08:00am, Wednesday, 26'th Feb 2025
FDA Fast Track Designation granted for Phentolamine Ophthalmic Solution 0.75% as treatment of significant chronic night driving impairment in keratorefractive patients with reduced mesopic vision Enro
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
07:30am, Wednesday, 26'th Feb 2025
Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) whose disease has progressed following treatment with platinum-bas
BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program
08:30am, Thursday, 20'th Feb 2025
– Underscores high unmet need for a therapeutic alternative to opioids and surgical interventions – – Reflects positive preliminary Phase 2 Safety and Efficacy data reported to date – – May
B2Gold Reports Q4 and Full Year 2024 Results; Achieved 2024 Total Gold Production and Consolidated Cost Guidance; Goose Project Remains On Track for First Gold in Q2 2025 and Total Capital Estimate Remains at C$1,540 Million; Q1 2025 Dividend of US$0.02 per Share Declared
06:00pm, Wednesday, 19'th Feb 2025
VANCOUVER, British Columbia, Feb. 19, 2025 (GLOBE NEWSWIRE) -- B2Gold Corp. (TSX: BTO, NYSE AMERICAN: BTG, NSX: B2G) (“B2Gold” or the “Company”) announces its operational and financial results
